Filing Details

Accession Number:
0001209191-18-059061
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-11-16 19:11:57
Reporting Period:
2018-11-14
Accepted Time:
2018-11-16 19:11:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492426 Horizon Pharma Plc HZNP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1349376 P Timothy Walbert C/O Horizon Pharma Plc
Connaught House, 1St Fl, 1 Burlington Rd
Dublin L2 4
Chairman, President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2018-11-14 104,334 $5.20 650,404 No 4 M Direct
Ordinary Shares Acquisiton 2018-11-14 107,219 $12.94 757,623 No 4 M Direct
Ordinary Shares Acquisiton 2018-11-14 196,794 $4.96 954,417 No 4 M Direct
Ordinary Shares Disposition 2018-11-14 408,347 $21.54 546,070 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2018-11-14 104,334 $0.00 104,334 $5.20
Ordinary Shares Stock Option (Right to Buy) Disposition 2018-11-14 107,219 $0.00 107,219 $12.94
Ordinary Shares Stock Option (Right to Buy) Disposition 2018-11-14 196,794 $0.00 196,794 $4.96
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-02-02 No 4 M Direct
0 2020-06-15 No 4 M Direct
0 2021-12-07 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2018.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.21 to $21.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The stock option is fully vested and exercisable. 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in 36 equal monthly installments thereafter.